longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Omeros

OMER

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 11.64, above the reasonable range, cheaper than 0.31% of the time in the past 5 years, and the industry ranks 14/256, the industry Median -1.39.

11.64xP/E
$20.08Stock price
$1.72Earnings per share
11.64xP/E
Stock price$20.08Earnings per share$1.72

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.29x
Typical range
-3.66x–5.46x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
BMYUSBristol Myers Squibb
13.83x62.25%$128.41B
GSKUSGSK
15.57x14.52%$100.34B
UCBJYUSUCB S.A.
18.36x--$46.77B
HLNUSHaleon
18.80x1.74%$40.79B
OTSKYUSOtsuka Pharmaceutical
14.35x--$37.15B
ZTSUSZoetis
11.13x6.81%$29.36B
ALPMYUSAstellas Pharma
11.70x--$27.29B
JAZZUSJazz Pharma
16.42x349.11%$15.45B
OPHLYUSOno Pharmaceutical
15.02x--$7.32B
INDVUSIndivior Pharmaceuticals
11.87x126.83%$4.23B
OGNUSOrganon
17.25x211.11%$3.61B
SNPHYUSSanten Pharmaceutical
14.36x--$3.55B
HRMYUSHarmony Biosciences
13.26x45.48%$2.40B
PBHUSPrestige Brands
12.84x7.48%$2.21B
GTBIFUSGreen Thumb Industries Inc.
14.17x--$1.80B
ANIPUSANI Pharma
16.69x51.20%$1.66B
OMERUSOmeros
11.64x1,913.34%$1.45B
PAHCUSPhibro Animal Health
14.03x26.75%$1.40B
CRONUSCronos
17.58x881.78%$1.23B
AMPHUSAmphastar Pharma
14.15x6.90%$1.11B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.